Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Morgan Stanley 20 th ...
AtriCure, Inc. (ATRC) Q2 2022 Earnings Conference Call August 2, 2022 16:30 ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants ...
AtriCure press release ( NASDAQ: ATRC ): Q2 GAAP EPS of -$0.32 misses by $0.03 . Revenue of $84.53M (+18.4% Y/Y) beats by $4.86M . Full year 2022 revenue is projected to be approximately $323 million to $333 million, reflecting growth of approximately 18% to 21...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a ...
Cryoport has done well to grow its top line in recent years and some bottom line figures have also fared well. Growth is expected to continue this year, but this doesn't make the company a wise investment. Shares look very expensive right now and are unlikely to offer material ups...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2022 financial results on...
AtriCure presents with numerous inflection points that sit on the distant horizon. However, data from its operating performance suggests it has to overcome numerous idiosyncratic headwinds. The company has printed a series of operating, net and FCF losses in the years to date. ...
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effec...
AtriCure Inc. (ATRC) Q1 2022 Results Conference Call May 3, 2022 04:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants Robbie Marcus - JPMorgan Danielle Antalffy - SVB Leerink John McAulay - Stifel Sam ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...